PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31911485-7	2020	In vitro, oxidative metabolism of alisertib was primarily mediated by CYP3A.	MLN 8237	34-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-75	
28852909-1	2018	Aim Two studies investigated the effect of gastric acid reducing agents and strong inducers/inhibitors of CYP3A4 on the pharmacokinetics of alisertib, an investigational Aurora A kinase inhibitor, in patients with advanced malignancies.	MLN 8237	140-149	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112	
34896433-5	2022	In addition, alisertib was characterized as a low- to moderate-affinity inhibitor of recombinant CYP3A4, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 isoenzymes, but without potential clinical relevance.	MLN 8237	13-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103